Market research
BLU BELLUS Health Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 16.06
- Dividend yield
- 0.0%
- Beta
- -0.28
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA07987C2040
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 16.06
- Dividend yield
- 0.0%
- Beta
- -0.28
About
About BELLUS Health Inc.
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BLU discussion.
5 years, 4 months ago
BELLUS Health Inc is currently in a long term downtrend where the price is trading 14.0% below its 200 day moving average.
From a valuation standpoint, the stock is 1054.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15464.1.
BELLUS Health Inc's total revenue sank by 44.1% to $4K since the same quarter in the previous year.
Its net income has increased by 27.2% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 1.6% to $-10M since the same quarter in the previous year.
Based on the above factors, BELLUS Health Inc gets an overall score of 2/5.